COMMUNIQUÉS West-GlobeNewswire

Sorevna Announces Strategic Expansion into Bath and Body Sector
12/01/2026
New York, USA, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Sorevna , a company in the cosmetics industry, today announced its planned entry into the bath and body care segment, expanding its existing product portfolio. The [...]
Nudj Health Names Dr. David Nash
12/01/2026
Global leader of Population Health and Public Accountability for Health Outcomes Joins Advisory Board SAN FRANCISCO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- JP Morgan Healthcare Conference -- Nudj Health, the leading AI- [...]
IBA – TRANSPARENCY NOTIFICATION
12/01/2026
(Article 14, paragraph 1 of the law of 2 May 2007 on the disclosure of major holdings) Louvain-la-Neuve, Belgium, January 12, 2026 06:00 PM Summary of the notification IBA (Ion Beam Applications), the world’s leading [...]
IBA SA – NOTIFICATION TRANSPARENCE
12/01/2026
(article 14, alinéa 1er de la loi du 2 mai 2007 relative à la publicité des participations importantes) Louvain-la-Neuve, Belgique, le 12 janvier 2026, 18:00 Résumé de la notification IBA (Ion Beam Applications SA), le [...]
SAFE GROUP NOMME CYRIL GONCALVES AU POSTE DE DIRECTEUR ADMINISTRATIF ET FINANCIER
12/01/2026
SAFE GROUP NOMME CYRIL GONCALVES AU POSTE DE DIRECTEUR ADMINISTRATIF ET FINANCIER Renforcement de l’équipe de direction Fleurieux-sur-l’Arbresle – France – 12 janvier 2026 – 18h - Safe (FR001400ZU25 – ALSAF), annonce [...]
Oncovita announces a strategic partnership with Infinitusbio.AI to explore the design and optimize the development of new therapeutic candidates from its Measovir® platform.
12/01/2026
Oncovita announces a strategic partnership with Infinitusbio.AI to explore the design and optimize the development of new therapeutic candidates from its Measovir® platform. San Diego, United-States and Paris, France – [...]
ZYUS Life Sciences Announces LIFE Offering of a minimum of C$15 Million and maximum of C$16 Million of Units
12/01/2026
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES SASKATOON, Saskatchewan, Jan. 12, 2026 (GLOBE NEWSWIRE) -- ZYUS Life Sciences Corporation (the " Company ") (TSXV: ZYUS), a [...]
Mixie Technologies, Inc. (PHCG) Announces CES Picks Award Recognition for HoloTwin LLC
12/01/2026
Recognition by TechRadar Pro at CES 2026 underscores the strategic rationale behind Mixie’s strategic investment in HoloTwin’s AI-driven digital twin technology for enterprise and smart infrastructure operations DENVER [...]
HealthEquity Announces Fiscal Year 2027 Outlook Presentation at J.P. Morgan Healthcare Conference
12/01/2026
DRAPER, Utah, Jan. 12, 2026 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ: HQY) (“HealthEquity” or the “Company”), the nation’s largest health savings account (“HSA") custodian by number of accounts and leading [...]
Achieve Life Sciences Confirms Promotion of Dr. Mark Rubinstein to Chief Medical Officer
12/01/2026
Experienced medical executive advances to permanent role following successful leadership as Interim CMO SEATTLE and VANCOUVER, British Columbia, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: [...]
ACCENT DATA PRESENTED AT 2026 ASCO GASTROINTESTINAL CANCER SYMPOSIUM
12/01/2026
HIGHLIGHTS Results from the Phase 2a ACCENT trial in pancreatic cancer have been presented at the specialist conference ASCO Gastrointestinal Cancer Symposium Updated data analysis continues to show that Narmafotinib [...]
CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones
12/01/2026
-2026 is poised to be a data- and milestone-rich year across the portfolio- -CASGEVY ® launch acceleration continues, supporting multi-billion-dollar potential- -Broad pipeline supported by leading gene-editing and [...]
Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs
12/01/2026
– First MIRACLE trial unblinding expected Q1 2026; Global trial now spans nine countries – Investigator-Initiated (IIT) funded pancreatic and brain cancer trials HOUSTON, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Moleculin [...]
Counterpart Health 2025 Results: How Better Clinical Decisions at Scale Improve Outcomes, Quality, and Cost
12/01/2026
Counterpart continues to demonstrate that unified data and real-time insights, delivered directly into the clinician’s workflow, drive measurable clinical and financial outcomes SAN FRANCISCO, Jan. 12, 2026 (GLOBE [...]
Alignment Healthcare Reports 31% Year-Over-Year Membership Growth to 275,300 as of Jan. 1, 2026
12/01/2026
Guides year-end 2026 health plan membership range of 290,000 to 296,000. Announces its expectation that consensus adjusted EBITDA of approximately $145 million in 2026 will be within its full-year 2026 guidance range. [...]
Kailera Therapeutics Announces First Participants Randomized in KaiNETIC Global Phase 3 Clinical Program of GLP-1/GIP Receptor Dual Agonist Ribupatide (KAI-9531)
12/01/2026
– Ribupatide (KAI-9531) aims to address critical need for greater weight loss, especially for people living with a BMI of 35 kg/m 2 or greater – – KaiNETIC program includes three Phase 3 clinical trials in adults living [...]
Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Development
12/01/2026
Pricing of $12.5 Million Registered Direct Offering & Concurrent Private Placement Offerings priced at-the-market under Nasdaq rules ALPHARETTA, Ga., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. ( [...]
Disc Medicine Highlights Recent Achievements and Key Business Objectives and Milestones for 2026
12/01/2026
Bitopertin was awarded the Commissioner’s National Priority Review Voucher (CNPV) and NDA is currently under FDA review Updated data from the Phase 2 study of DISC-0974 in patients with myelofibrosis (MF) and anemia [...]
Xenon Outlines Key Upcoming Milestones at the 2026 J.P. Morgan Healthcare Conference
12/01/2026
Phase 3 X-TOLE2 topline data for azetukalner in FOS expected March 2026 followed by anticipated NDA submission in H2 2026 Five additional Phase 3 azetukalner studies continuing to enroll patients in multiple indications [...]

Pages

Other news

Test 2

22/10/2026

Lorem ipsum

Test 1

22/10/2026

Lorem upsum